NEWRON PHARMA N chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.33
Dividend & YieldN/Afr (N/A)
Beta 0.64
Market capitalization 24.09M
Operating cash flow -8.32M
ESG Scores unknown

Company description

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio10.79
Working Capital-0.42
Return On Equity-4.8
Debt To Equity13.69
Fixed Asset Ratio0
Fixed Interest Cover-4.23

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -1.19M 707k 557k -3.95M
Total Cashflows From Investing Activities 2.96M -932k -616k 8.42M
Net Borrowings -154k 17.34M 7.37M 14.83M
Total Cash From Financing Activities -27k 17.34M 7.37M 14.83M
Change To Operating Activities -2k -12k 1.94M 1.93M
Issuance Of Stock 51k
Net Income -15.04M -20.21M -21M -14.9M
Change In Cash -13.02M -5.57M -8.84M 11.81M
Effect Of Exchange Rate
Total Cash From Operating Activities -15.95M -21.98M -15.59M -11.45M
Depreciation 192k 206k 219k 209k
Change To Account Receivables 2.99M -158k 1.23M 1.75M
Other Cashflows From Financing Activities 76k
Change To Netincome -2.91M -2.51M 1.47M 3.51M
Capital Expenditures -34k -51k -34k -20k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 9.84M 17.44M 14.85M 10.72M
Income Before Tax -15.02M -20.16M -19.62M -14.88M
Net Income -15.04M -20.21M -21M -14.9M
Selling General Administrative 9.17M 10.5M 8.47M 7.39M
Gross Profit 4.03M 7.04M 5.26M 5.76M
Ebit -14.98M -20.9M -18.07M -12.36M
Operating Income -14.98M -20.9M -18.07M -12.36M
Interest Expense -56k -572k -2.24M -2.92M
Income Tax Expense 16k 45k 1.38M 17k
Total Revenue 4.03M 7.04M 5.26M 5.76M
Cost Of Revenue
Total Other Income ExpenseNet -41k 737k -1.55M -2.53M
Net Income From Continuing Ops -15.04M -20.21M -21M -14.9M
Net Income Applicable To Common Shares -15.04M -20.21M -21M -14.9M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 5.16M 23.49M 33.95M 47.38M
Total Stockholder Equity 54.84M 36.8M 17.25M 3.11M
Other Current Liabilities 717k 730k 2.19M 899k
Total Assets 60M 60.29M 51.2M 50.49M
Common Stock 3.57M 3.57M 3.57M 3.57M
Other Current Assets
Retained Earnings -20.2M -25.34M -26.16M -20.12M
Treasury Stock 10.13M 12.26M 13.73M 14.55M
Cash 27.62M 22.05M 13.21M 25.02M
Total Current Liabilities 4.43M 5.59M 6.89M 3.65M
Other Stockholder Equity 10.13M 12.26M 13.73M 14.55M
Property, Plant, and Equipment 374k 252k 734k 577k
Total Current Assets 59.51M 45.49M 37.87M 39.43M
Net Tangible Assets 54.81M 36.78M 17.23M 3.1M
Net Receivables 15.44M 5.01M 6.62M 4.05M
Accounts Payable 1.15M 2.41M 1.27M 1.5M


Insider Transactions

Here are the insider transactions of stock shares related to NEWRON PHARMA N:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to NEWRON PHARMA N. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on NEWRON PHARMA N

Here is the result of two systematic investment strategies applied to NEWRON PHARMA N. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on NEWRON PHARMA N

The following chart shows the equity curve of the two systematic investment strategies applied to NEWRON PHARMA N:

NEWRON PHARMA N automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -38.47% on the backtest period.

Performance at glance

Performance

-38.47 %

Latent gain

-576.47 fr

Invested capital

1498.47 fr

Annualized return

-9.25 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on NEWRON PHARMA N

This is the result of two momentum investment strategies applied to NEWRON PHARMA N. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on NEWRON PHARMA N

The following chart shows all the entries opened by the momentum investment system on NEWRON PHARMA N:

NEWRON PHARMA N momentum entries
  • The first momentum investment strategy would give -46.31% of return on NEWRON PHARMA N. That represents -2316.93fr of latent gain with 5002.93fr of employed capital.
  • The second momentum investment strategy would give -39.87% of return on NEWRON PHARMA N. That represents -1094.05fr of latent gain with 2744.05fr of employed capital.
Performance at glance (1Q Momentum)

Performance

-46.31 %

Latent gain

-2316.93 fr

Invested capital

5002.93 fr

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-39.87 %

Latent gain

-1094.05 fr

Invested capital

2744.05 fr

Annualized return

-10.83 %

Momentum equity curve on NEWRON PHARMA N

The following chart shows the equity curve of the two momentum strategies applied to NEWRON PHARMA N:

NEWRON PHARMA N momentum equity

Note: the dividends potentially given by NEWRON PHARMA N are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on NEWRON PHARMA N

The following chart shows the employed capital evolution of the two momentum strategies on NEWRON PHARMA N since the beginning:

NEWRON PHARMA N

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250fr, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000fr.


Buy the dip strategy result on NEWRON PHARMA N

Buy the dip entry openings on NEWRON PHARMA N

NEWRON PHARMA N

The performance achieved by the robo-advisor on NEWRON PHARMA N is 0%. That represents 0.0$ of latent gain with 0.0fr of employed capital. The following chart shows NEWRON PHARMA N stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of NEWRON PHARMA N, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 fr

Invested capital

0.0 fr

Annualized return

0.0 %

Equity curve of the strategy applied to NEWRON PHARMA N

The following chart shows the result of the investment strategy applied to NEWRON PHARMA N:

NEWRON PHARMA N

Note: the dividends potentially given by NEWRON PHARMA N are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on NEWRON PHARMA N

The following chart shows the employed capital evolution since the beginning of the investment strategy on NEWRON PHARMA N:

NEWRON PHARMA N

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on NEWRON PHARMA N

In this section, I will compare the three previous investment strategies applied to NEWRON PHARMA N.

Equity curve comparison on NEWRON PHARMA N

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

NEWRON PHARMA N investment strategy comparison

Employed capital comparison on NEWRON PHARMA N

NEWRON PHARMA N investment comparison

Performance comparison on NEWRON PHARMA N

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -38.47% -576.47fr 1498.47fr -9.25%
Momentum 1 quarter -46.31% -2316.93fr 5002.93fr -11.81%
Momentum 2 quarters -39.87% -1094.05fr 2744.05fr -10.83%
Non-directional 0% 0.0fr 0.0fr 0.0%
Annualized return comparison

Automatic investment

-9.25 %

Momentum 1Q

-10.83 %

Momentum 2Q

-10.83 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with NEWRON PHARMA N:


Company information

Company name NEWRON PHARMA N
Country Italy
City Bresso
Address Via Antonio Meucci 3
Phone 39 02 610 3461
Website www.newron.com
FullTime employees 25
Industry Biotechnology
Sector Healthcare
Exchange XSWX
Ticker NWRN.XSWX
Market www.six-group.com

NEWRON PHARMA N ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown